Advanced search
1 file | 171.37 KB Add to list

LC-MS characterization and cell-binding properties of chelate modified somatropin

Evelien Wynendaele (UGent) , Koen Mertens (UGent) , Ewald Pauwels (UGent) , Christophe Van De Wiele (UGent) and Bart De Spiegeleer (UGent)
Author
Organization
Project
Abstract
Somatropin, a recombinant protein containing 191 amino acids, is derived from the endogenous human growth hormone, somatotropin. This protein is clinically used in children and adults with inadequate endogenous growth hormone to stimulate a normal bone and muscle growth. In addition, somatropin is recently being investigated for the diagnosis and radiotherapy of certain hormonal cancers. In some of these cancers, over-expression of the human growth hormone receptor (hGHR) is described. The modification of the protein with a chelating agent like NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) allows the inclusion of metals coupled to the protein. The NOTA unit is selectively introduced on a lysine side chain. As site-specific labelling is necessary to avoid active region interactions (1-16, 41-68, 103-119 and 167-175), characterization of the chelate-modified somatropin is indispensable. Therefore, we have applied an enzymatic digestion procedure using trypsin, chymotrypsin and a combination of both enzymes. The resulting peptides were then monitored using HPLC-MSn, allowing the investigation of the exact amino acid modifications. The use of a mixture of trypsin and chymotrypsin gave an enhanced information efficiency. Moreover, the intact protein, without enzymatic degradation, was analysed on a protein HPLC column using UV detection for quantification and ESI-MS/MS for characterization. Based upon the HPLC-MSn results of the digested somatropin, the chelating molecule is mainly bound to a specific lysine amino acid that is located away from the receptor binding site. Therefore, the cell-binding functionality of the characterized NOTA-somatropin is measured, using a HepG2 cell line.
Keywords
Somatropin, Cell-binding, Chelate

Downloads

  • 2010-475b Poster Drug Analysis - Somatropin.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 171.37 KB

Citation

Please use this url to cite or link to this publication:

MLA
Wynendaele, Evelien, et al. “LC-MS Characterization and Cell-Binding Properties of Chelate Modified Somatropin.” Drug Analysis 2010, Abstracts, 2010.
APA
Wynendaele, E., Mertens, K., Pauwels, E., Van De Wiele, C., & De Spiegeleer, B. (2010). LC-MS characterization and cell-binding properties of chelate modified somatropin. Drug Analysis 2010, Abstracts. Presented at the Drug Analysis 2010, University of Antwerp, Belgium.
Chicago author-date
Wynendaele, Evelien, Koen Mertens, Ewald Pauwels, Christophe Van De Wiele, and Bart De Spiegeleer. 2010. “LC-MS Characterization and Cell-Binding Properties of Chelate Modified Somatropin.” In Drug Analysis 2010, Abstracts.
Chicago author-date (all authors)
Wynendaele, Evelien, Koen Mertens, Ewald Pauwels, Christophe Van De Wiele, and Bart De Spiegeleer. 2010. “LC-MS Characterization and Cell-Binding Properties of Chelate Modified Somatropin.” In Drug Analysis 2010, Abstracts.
Vancouver
1.
Wynendaele E, Mertens K, Pauwels E, Van De Wiele C, De Spiegeleer B. LC-MS characterization and cell-binding properties of chelate modified somatropin. In: Drug analysis 2010, Abstracts. 2010.
IEEE
[1]
E. Wynendaele, K. Mertens, E. Pauwels, C. Van De Wiele, and B. De Spiegeleer, “LC-MS characterization and cell-binding properties of chelate modified somatropin,” in Drug analysis 2010, Abstracts, University of Antwerp, Belgium, 2010.
@inproceedings{1178066,
  abstract     = {{Somatropin, a recombinant protein containing 191 amino acids, is derived from the endogenous human growth hormone, somatotropin. This protein is clinically used in children and adults with inadequate endogenous growth hormone to stimulate a normal bone and muscle growth. In addition, somatropin is recently being investigated for the diagnosis and radiotherapy of certain hormonal cancers. In some of these cancers, over-expression of the human growth hormone receptor (hGHR) is described. 
The modification of the protein with a chelating agent like NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) allows the inclusion of metals coupled to the protein. The NOTA unit is selectively introduced on a lysine side chain. As site-specific labelling is necessary to avoid active region interactions (1-16, 41-68, 103-119 and 167-175), characterization of the chelate-modified somatropin is indispensable. Therefore, we have applied an enzymatic digestion procedure using trypsin, chymotrypsin and a combination of both enzymes. The resulting peptides were then monitored using HPLC-MSn, allowing the investigation of the exact amino acid modifications. The use of a mixture of trypsin and chymotrypsin gave an enhanced information efficiency. Moreover, the intact protein, without enzymatic degradation, was analysed on a protein HPLC column using UV detection for quantification and ESI-MS/MS for characterization. Based upon the HPLC-MSn results of the digested somatropin, the chelating molecule is mainly bound to a specific lysine amino acid that is located away from the receptor binding site. Therefore, the cell-binding functionality of the characterized NOTA-somatropin is measured, using a HepG2 cell line.}},
  author       = {{Wynendaele, Evelien and Mertens, Koen and Pauwels, Ewald and Van De Wiele, Christophe and De Spiegeleer, Bart}},
  booktitle    = {{Drug analysis 2010, Abstracts}},
  keywords     = {{Somatropin,Cell-binding,Chelate}},
  language     = {{eng}},
  location     = {{University of Antwerp, Belgium}},
  title        = {{LC-MS characterization and cell-binding properties of chelate modified somatropin}},
  year         = {{2010}},
}